We next sought to establish the cell-type dependence of TPr inhibition on platelet-tumor cell adhesion with a series of treatment protocols that would activate/inhibit TPr selectively in platelets, tumor cells, or both in combination by using CD-61 as a measure of platelet activation (Supplementary Fig. 1). The gene discussed is TPR; the disease is neoplasm.